Table 2.
Murine models of medulloblastoma shown with underlying genetics, mechanism of engineering and incidence. Abbreviations: TG = transgenic, KO = knockout.
| Genetics | Mechanism | Incidence | Reference |
|---|---|---|---|
| Ptch+/− | Conventional KO | 14%–19% by 10 months | 23, 44, 98 |
| Ptch+/− | Conventional KO; irradiation | 100% by 10 months | 54, 55 |
| Ptch+/−; p53−/− | Conventional KO | 100% by 2–3 months | (89) |
| Ptch+/−; Ptch2±/− | Conventional KO | 17% by 10 months | (44) |
| Ptch+/− | Conditional KO (GFAP‐Cre, Math1‐Cre) | 100% by 1–3 months | (95) |
| ND2‐SmoA1 | TG | 94% by 2 months | 26, 28 |
| SmoM2 | Conditional TG (GFAP‐Cre, Math1‐Cre, Olig2‐Cre, Tlx‐Cre) | 100% by 2–4 months* | (69) |
| Sufu+/−; p53−/− | Conventional KO | 58% by 10 months | (42) |
| Shh | RCAS | 9%–34% by 3 months | 7, 49, 60, 61 |
| Shh; c‐myc/Akt/IGF2 | RCAS | 23%–48% by 3 months | 60, 61 |
| Shh; n‐myc | RCAS | 78% by 3 months | (7) |
| Shh; Bcl‐2 | RCAS | 78% by 3 months | (49) |
| Rb±/−; p53−/− | Conditional KO (GFAP‐Cre) | 25%–100% by 2–7 months | (48) |
| Ink4c±/−; p53±/− | Conventional and conditional KO (Nestin‐Cre); irradiation | 20%–100% by 5 months | (81) |
| Ptch+/−; Ink4c±/− | Conventional KO | 40%–50% by 9 months | (81) |
| Lig4−/−; p53−/− | Conventional KO | 100% by 2 months | (43) |
| Brca2−/−; p53±/− | Conventional and conditional KO (Nestin‐Cre) | 72%–83% by 4–8 months | (17) |
| Xrcc4−/−; p53−/− | Conventional and conditional KO (Nestin‐Cre) | 100% by 6 months | (94) |
*
Estimated from reported average latency.